Cabaletta Bio (CABA) revenue and earnings history
Cabaletta Bio's annual figures for 8 fiscal years, as filed with the SEC.
Revenue and net income, 8 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Dec 31, 2025 | — | −$172M | −$168M | −$131M | $1.23M | −$132M | $20.9M | — | — | $83M | — | 10-K |
| 2024ended Dec 31, 2024 | — |
The latest quarter, insider trades and fund moves: Cabaletta Bio (CABA) on OQRO.
Common questions
Has Cabaletta Bio been profitable?
It reported a net loss in 8 of the years shown (2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025). The highest net income was −$12.2M in fiscal 2018.
What was Cabaletta Bio's free cash flow in fiscal 2025?
−$132M: operating cash flow of −$131M minus capital expenditure of $1.23M. OQRO calculates free cash flow this way from the two filed lines.
Does Cabaletta Bio buy back shares or pay dividends?
None of the 8 annual reports shown tags a share buyback or a dividend payment in the standard US taxonomy.
Why is earnings per share not in this table?
Where these figures come from
The SEC’s companyfacts data: every figure Cabaletta Bio tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.
